Document Detail

Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia.
MedLine Citation:
PMID:  19698415     Owner:  NLM     Status:  In-Data-Review    
The effect of treatment (28 days) with zopiclone, triazolam, flunitrazepam and placebo on sleep quality and daytime well-being was proven in a randomised, double-blind, parallel group, multicentre study in private practice. Results of an exploratory statistic of treatment efficacy in a subgroup of 1,291 patients suffering from insomnia are presented. Patients met the following criteria: insomnia lasting at least four weeks and the presence of at least two of the following: 1) sleep latency >/= 45 minutes, 2) total sleep time </= 6 hours, and 3) nocturnal awakening >/=3 times. Treatment efficacy was assessed according to the following factors: either a shortening of sleep latency by at least 15 minutes, or prolongation of total sleep time by at least 20%, or reduction of the number of nocturnal awakenings to three or less and a refreshed feeling in the morning as well as no impairment in daytime well-being due to tiredness or anxiety. The total response rate was markedly higher with zopiclone (42.3%; p = 0.0003) than with placebo (29.0%). Triazolam (36.6%; p = 0.0905) and flunitrazepam (33.1%; p = 0.3401) were also more effective than the placebo, but they both tended to have a lower response rate than with zopiclone (p = 0.1199 and 0.0151, respectively). Total response was found to be essentially a reflection of the response of the socially important parameter of daytime well-being. These results suggest that zopiclone is more effective in the treatment of insomnia than either triazolam or flunitrazepam. Since the response of daytime well-being to therapy was generally poor, this parameter embodies the next main therapeutic challenge in the treatment of patients with insomnia.
G Hajak; P Clarenbach; W Fischer; W Haase; B Bandelow; L Adler; E Rüther
Related Documents :
15701215 - Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
7040615 - A more efficient biofeedback procedure for the treatment of nocturnal bruxism.
8341895 - Consulting about insomnia: a method and some preliminary data.
1813605 - Treating insomnia: pharmacological and nonpharmacological approaches.
7056735 - The composition of sleep-promoting factor isolated from human urine.
7309435 - Amblyopic eyes have longer reaction times.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European psychiatry : the journal of the Association of European Psychiatrists     Volume:  10 Suppl 3     ISSN:  0924-9338     ISO Abbreviation:  Eur. Psychiatry     Publication Date:  1995  
Date Detail:
Created Date:  2009-08-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111820     Medline TA:  Eur Psychiatry     Country:  France    
Other Details:
Languages:  eng     Pagination:  173s-9s     Citation Subset:  -    
Department of Psychiatry, University of Göttingen, von-Siebold-Str 5, 57075 Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Zopiclone in the treatment of insomnia in depressed patients.
Next Document:  Dermatoglyphic patterns in subtypes of schizophrenia.